Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof‐of‐concept study
Gideon M. Hirschfield(University Health Network), Richard Strauß(Hennepin County Medical Center), Marlyn J. Mayo(Southwestern Medical Center), Ivo Nnane(Janssen (United States)), B. Dasgupta(Cornell University), Cynthia Levy(University of Miami), Keith D. Lindor(Mayo Clinic), Hanns–Ulrich Marschall(University of Padua), Bin Zou(Janssen (United States)), David Jones(Memorial Sloan Kettering Cancer Center), Katherine Li(Centro de Investigación del Cáncer), M. Eric Gershwin(University of California, Davis), Carlo Selmi(University of Milan), Jewel Johanns(Johnson & Johnson (United States))
Cited by 132
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k